Reversal of established lupus nephritis and prolonged survival of New Zealand Black x New Zealand White mice treated with the topoisomerase I inhibitor irinotecan

Journal of Immunology

Volumn 184, Issue 4, 2010, Pages 2175-2182

  Frese Schaper, Manuela ^a   Zbaeren, Jakob ^a   Gugger, Mathias ^a   Monestier, Marc ^b   Frese, Steffen ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IRINOTECAN; LACTATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GLOMERULUS BASEMENT MEMBRANE; HISTOPATHOLOGY; IMMUNE COMPLEX DEPOSITION; KIDNEY; KIDNEY CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE STRAIN; NEW ZEALAND BLACK MOUSE; NEW ZEALAND WHITE MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REMISSION; SINGLE STRANDED DNA BREAK; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; ANIMAL; AUTOIMMUNE DISEASE; CROSS BREEDING; DRUG ANTAGONISM; ENZYMOLOGY; IMMUNOLOGY; MORTALITY; PHYSIOLOGY; RANDOMIZATION; SURVIVAL; TIME;

ANIMALS; AUTOIMMUNE DISEASES; CAMPTOTHECIN; CROSSES, GENETIC; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; LUPUS NEPHRITIS; MICE; MICE, INBRED NZB; PROTEINURIA; RANDOM ALLOCATION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 77949887121     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903153     Document Type: Article

References (43)

1. Hochberg, M. C., D. L. Perlmutter, T. A. Medsger, V. Steen, M. H. Weisman, B. White, and F. M. Wigley. 1995. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 4: 454-456.
2. Cameron, J. S. 1999. Lupus nephritis. J. Am. Soc. Nephrol. 10: 413-424.
3. Cervera, R., M. A. Khamashta, J. Font, G. D. Sebastiani, A. Gil, P. Lavilla, J. C. Mejía, A. O. Aydintug, H. Chwalinska-Sadowska, E. de Ramón, et al; European Working Party on Systemic Lupus Erythematosus. 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82: 299-308.
4. Borchers, A., A. A. Ansari, T. Hsu, D. H. Kono, and M. E. Gershwin. 2000. The pathogenesis of autoimmunity in New Zealand mice. Semin. Arthritis Rheum. 29: 385-399.
5. Hahn, B. H. 2001. Lessons in lupus: the mighty mouse. Lupus 10: 589-593.
6. Zoja, C., D. Corna, G. Benedetti, M. Morigi, R. Donadelli, A. Guglielmotti, M. Pinza, T. Bertani, and G. Remuzzi. 1998. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 53: 726-734.
7. Ramos-Barrón, A., C. Piñera-Haces, C. Gómez-Alamillo, I. Santiuste-Torcida, J. C. Ruiz, L. Buelta-Carrillo, R. Merino, A. L. de Francisco, and M. Arias. 2007. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 16: 775-781.
8. Bahjat, F. R., P. R. Pine, A. Reitsma, G. Cassafer, M. Baluom, S. Grillo, B. Chang, F. F. Zhao, D. G. Payan, E. B. Grossbard, and D. I. Daikh. 2008. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58: 1433-1444.
9. Neubert, K., S. Meister, K. Moser, F. Weisel, D. Maseda, K. Amann, C. Wiethe, T. H. Winkler, J. R. Kalden, R. A. Manz, and R. E. Voll. 2008. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14: 748-755.
10. Tao, X., F. Fan, V. Hoffmann, C. Y. Gao, N. S. Longo, P. Zerfas, and P. E. Lipsky. 2008. Effective therapy for nephritis in (NZB x NZW)F1 mice with triptolide and tripdiolide, the principal active components of the Chinese herbal remedy Tripterygium wilfordii Hook F. Arthritis Rheum. 58: 1774-1783.
11. Casey, T. P. 1968. Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis. Blood 32: 436-444.
12. Casey, T. P. 1973. Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: beneficial effect complicated by development of malignant lymphomas. N. Z. Med. J. 79: 290-295.
13. Foell, J., S. Strahotin, S. P. O'Neil, M. M. McCausland, C. Suwyn, M. Haber, P. N. Chander, A. S. Bapat, X. J. Yan, N. Chiorazzi, et al. 2003. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J. Clin. Invest. 111: 1505-1518.
14. Steinberg, A. D., M. C. Gelfand, J. A. Hardin, and D. T. Lowenthal. 1975. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum. 18: 9-14.
15. Schiffer, L., J. Sinha, X. Wang, W. Huang, G. von Gersdorff, M. Schiffer, M. P. Madaio, A. Davidson, and G. Von Gonsdorff. 2003. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171: 489-497. (Pubitemid 36745324)
16. Rodriguez, W., C. Mold, M. Kataranovski, J. Hutt, L. L. Marnell, and T. W. Du Clos. 2005. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum. 52: 642-650.
17. Houssiau, F. A., C. Vasconcelos, D. D'Cruz, G. D. Sebastiani, Ede. R. Garrido Ed, M. G. Danieli, D. Abramovicz, D. Blockmans, A. Mathieu, H. Direskeneli, et al. 2002. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46: 2121-2131.
18. Contreras, G., V. Pardo, B. Leclercq, O. Lenz, E. Tozman, P. O'Nan, and D. Roth. 2004. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350: 971-980.
19. Clark, W. F., and J. M. Sontrop. 2008. What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials? Clin. J. Am. Soc. Nephrol. 3: 895-898.
20. Corna, D., M. Morigi, D. Facchinetti, T. Bertani, C. Zoja, and G. Remuzzi. 1997. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 51: 1583-1589. (Pubitemid 27239915)
21. McMurray, R. W., K. B. Elbourne, A. Lagoo, and S. Lal. 1998. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. J. Rheumatol. 25: 2364-2370.
22. Frese, S., M. Frese-Schaper, A. C. Andres, D. Miescher, B. Zumkehr, and R. A. Schmid. 2006. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res. 66: 5867-5874.
23. Rothenberg, M. L. 1998. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin. Oncol. 25(5), Suppl 11)39-46.
24. Ulukan, H., and P. W. Swaan. 2002. Camptothecins: a review of their chemotherapeutic potential. Drugs 62: 2039-2057.
25. Frese, S., F. Pirnia, D. Miescher, S. Krajewski, M. M. Borner, J. C. Reed, and R. A. Schmid. 2003. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22: 5427-5435.
26. Cabaud, P. G., and F. Wroblewski. 1958. Colorimetric measurement of lactic dehydrogenase activity of body fluids. Am. J. Clin. Pathol. 30: 234-236.
27. Hsiang, Y. H., R. Hertzberg, S. Hecht, and L. F. Liu. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14878.
28. Frankfurt, O. S. 1990. Decreased stability of DNA in cells treated with alkylating agents. Exp. Cell Res. 191: 181-185.
29. Lee, J. Y., P. T. Huerta, J. Zhang, C. Kowal, E. Bertini, B. T. Volpe, and B. Diamond. 2009. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat. Med. 15: 91-96.
30. Yamadori, I., T. Yoshino, E. Kondo, L. Cao, T. Akagi, Y. Matsuo, and J. Minowada. 1998. Comparison of two methods of staining apoptotic cells of leukemia cell lines. Terminal deoxynucleotidyl transferase and DNA polymerase I reactions. J. Histochem. Cytochem. 46: 85-90.
31. Chen, M., P. M. Kochanek, S. C. Watkins, K. L. Jin, R. Draviam, P. D. Nathaniel, R. Pinto, D. W. Marion, S. H. Graham, and S. H. Graham; Clark RSB. 2001. Detection of single- and double-strand DNA breaks after traumatic brain injury in rats: comparison of in situ labeling techniques using DNA polymerase I, the Klenow fragment of DNA polymerase I, and terminal deoxynucleotidyl transferase. J. Neurotrauma 18: 675-689.
32. Daikh, D. I., and D. Wofsy. 2001. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166: 2913-2916.
33. Vanhoefer, U., A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum. 2001. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19: 1501-1518.
34. Hsiang, Y. H., M. G. Lihou, and L. F. Liu. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49: 5077-5082.
35. Katz, J. B., W. Limpanasithikul, and B. Diamond. 1994. Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med. 180: 925-932.
36. Bernstein, K. A., R. D. Valerio, and J. B. Lefkowith. 1995. Glomerular binding activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J. Immunol. 154: 2424-2433.
37. Zhao, Z., E. Weinstein, M. Tuzova, A. Davidson, P. Mundel, P. Marambio, and C. Putterman. 2005. Cross-reactivity of human lupus anti-DNA antibodies with α-actinin and nephritogenic potential. Arthritis Rheum. 52: 522-530.
38. Casciola-Rosen, L. A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179: 1317-1330.
39. Schmidt-Acevedo, S., B. Pérez-Romano, and A. Ruiz-Argüelles. 2000. 'LE cells' result from phagocytosis of apoptotic bodies induced by antinuclear antibodies. J. Autoimmun. 15: 15-20.
40. Kalaaji, M., E. Mortensen, L. Jørgensen, R. Olsen, and O. P. Rekvig. 2006. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am. J. Pathol. 168: 1779-1792.
41. Seery, J. P., V. Cattell, and F. M. Watt. 2001. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl- (β-o-methyl)-luoromethylketone. J. Immunol. 167: 2452-2455.
42. Makino, H., H. Sugiyama, Y. Yamasaki, Y. Maeshima, J. Wada, and N. Kashihara. 2003. Glomerular cell apoptosis in human lupus nephritis. Virchows Arch. 443: 67-77.
43. Seredkina, N., S. N. Zykova, and O. P. Rekvig. 2009. Progression of murine lupus nephritis is linked to acquired renal Dnase1 deficiency and not to upregulated apoptosis. Am. J. Pathol. 175: 97-106.